The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shrikant, P.
Right arrow Articles by Mescher, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shrikant, P.
Right arrow Articles by Mescher, M. F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 1999, 162: 2858-2866.
Copyright © 1999 by The American Association of Immunologists

Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness1

Protul Shrikant and Matthew F. Mescher2

Center for Immunology, University of Minnesota, Minneapolis, MN 55455

Activation of Ag-specific CD8+ T cells in response to syngeneic tumor has been visualized by adoptive transfer of CD8+ T cells from OT-I mice, with a transgenic TCR specific for H-2Kb and an OVA peptide, into Thy-1 congenic recipients. Intraperitoneal challenge with E.G7, the EL-4 thymoma transfected with OVA, results in activation and clonal expansion of the OT-I cells in the peritoneal cavity and transient control of tumor growth. However, within 2 days after becoming activated, the OT-I cells migrate out of the peritoneal cavity into the spleen and lymph nodes, and tumor growth resumes in the peritoneal cavity. The OT-I cells in lymph nodes and spleen have lytic effector activity, but exhibit split anergy in that they cannot proliferate in response to Ag unless exogenous IL-2 is provided. The failure to remain at the tumor site and continue to control tumor growth is not due to selection of Ag loss variants or development of suppression. These results suggest that effective CD8-targeted immunotherapy may depend less on enhancing the initial activation and more on sustaining the response at the appropriate location and/or reactivating cells that have left the site of tumor growth and become nonresponsive.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Beyer, J. Karbach, M. R. Mallmann, T. Zander, D. Eggle, S. Classen, S. Debey-Pascher, M. Famulok, E. Jager, and J. L. Schultze
Cancer Vaccine Enhanced, Non-Tumor-Reactive CD8+ T Cells Exhibit a Distinct Molecular Program Associated with "Division Arrest Anergy"
Cancer Res., May 15, 2009; 69(10): 4346 - 4354.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. M. Huntoon, Y. Wang, C. A. Eppolito, K. W. Barbour, F. G. Berger, P. A. Shrikant, and H. Baumann
The acute phase protein haptoglobin regulates host immunity
J. Leukoc. Biol., July 1, 2008; 84(1): 170 - 181.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson
CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism
Clin. Cancer Res., December 1, 2007; 13(23): 7172 - 7180.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Oizumi, N. Strbo, S. Pahwa, V. Deyev, and E. R. Podack
Molecular and Cellular Requirements for Enhanced Antigen Cross-Presentation to CD8 Cytotoxic T Lymphocytes
J. Immunol., August 15, 2007; 179(4): 2310 - 2317.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Wallace, D. F. LaRosa, V. Kapoor, J. Sun, G. Cheng, A. Jassar, A. Blouin, L.-M. Ching, and S. M. Albelda
The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes
Cancer Res., July 15, 2007; 67(14): 7011 - 7019.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Z. Xiao, J. M. Curtsinger, M. Prlic, S. C. Jameson, and M. F. Mescher
The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses
Int. Immunol., June 1, 2007; 19(6): 733 - 743.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol., June 1, 2007; 178(11): 6752 - 6760.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Q. Li, C. Eppolito, K. Odunsi, and P. A. Shrikant
IL-12-Programmed Long-Term CD8+ T Cell Responses Require STAT4
J. Immunol., December 1, 2006; 177(11): 7618 - 7625.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Horton, I. Frank, R. Baydo, E. Jalbert, J. Penn, S. Wilson, J. P. McNevin, M. D. McSweyn, D. Lee, Y. Huang, et al.
Preservation of T Cell Proliferation Restricted by Protective HLA Alleles Is Critical for Immune Control of HIV-1 Infection
J. Immunol., November 15, 2006; 177(10): 7406 - 7415.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Hollenbaugh and R. W. Dutton
IFN-{gamma} Regulates Donor CD8 T Cell Expansion, Migration, and Leads to Apoptosis of Cells of a Solid Tumor.
J. Immunol., September 1, 2006; 177(5): 3004 - 3011.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. C. McKenna and J. A. Kapp
Accumulation of Immunosuppressive CD11b+ Myeloid Cells Correlates with the Failure to Prevent Tumor Growth in the Anterior Chamber of the Eye
J. Immunol., August 1, 2006; 177(3): 1599 - 1608.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl
A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model
J. Immunol., July 1, 2006; 177(1): 155 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. W. Overwijk, K. E. de Visser, F. H. Tirion, L. A. de Jong, T. W. H. Pols, Y. U. van der Velden, J. G. van den Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al.
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant
J. Immunol., May 1, 2006; 176(9): 5213 - 5222.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Vianello, N. Papeta, T. Chen, P. Kraft, N. White, W. K. Hart, M. F. Kircher, E. Swart, S. Rhee, G. Palu, et al.
Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control.
J. Immunol., March 1, 2006; 176(5): 2902 - 2914.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. N. Hwang, Z. Yu, D. C. Palmer, and N. P. Restifo
The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor
Cancer Res., January 15, 2006; 66(2): 1132 - 1138.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Huang, N. Obholzer, R. Fayad, and L. Qiao
Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth
J. Immunol., September 1, 2005; 175(5): 3110 - 3116.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Benigni, V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino
Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk
J. Immunol., July 15, 2005; 175(2): 739 - 748.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. C. Morris, A. Tsallios, G. M. Bendle, S.-a. Xue, and H. J. Stauss
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection
PNAS, May 31, 2005; 102(22): 7934 - 7939.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino
The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration
J. Immunol., March 15, 2005; 174(6): 3317 - 3325.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
G. Zhou, Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson
Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression
J. Exp. Med., December 20, 2004; 200(12): 1581 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-J. Lee, L. Myers, G. Muralimohan, J. Dai, Y. Qiao, Z. Li, R. S. Mittler, and A. T. Vella
4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function
J. Immunol., September 1, 2004; 173(5): 3002 - 3012.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Moroz, C. Eppolito, Q. Li, J. Tao, C. H. Clegg, and P. A. Shrikant
IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21
J. Immunol., July 15, 2004; 173(2): 900 - 909.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Boissonnas, C. Combadiere, E. Lavergne, M. Maho, C. Blanc, P. Debre, and B. Combadiere
Antigen Distribution Drives Programmed Antitumor CD8 Cell Migration and Determines Its Efficiency
J. Immunol., July 1, 2004; 173(1): 222 - 229.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Salem, A. N. Kadima, Y. Zhou, C. L. Nguyen, M. P. Rubinstein, M. Demcheva, J. N. Vournakis, D. J. Cole, and W. E. Gillanders
Paracrine Release of IL-12 Stimulates IFN-{gamma} Production and Dramatically Enhances the Antigen-Specific T Cell Response after Vaccination with a Novel Peptide-Based Cancer Vaccine
J. Immunol., May 1, 2004; 172(9): 5159 - 5167.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Bansal-Pakala, B. S. Halteman, M. H.-Y. Cheng, and M. Croft
Costimulation of CD8 T Cell Responses by OX40
J. Immunol., April 15, 2004; 172(8): 4821 - 4825.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman
Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases
Cancer Res., March 15, 2004; 64(6): 2183 - 2191.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. M. Richards, S. L. Dalheimer, B. D. Ehst, T. L. Vanasek, M. K. Jenkins, M. I. Hertz, and D. L. Mueller
Indirect Minor Histocompatibility Antigen Presentation by Allograft Recipient Cells in the Draining Lymph Node Leads to the Activation and Clonal Expansion of CD4+ T Cells That Cause Obliterative Airways Disease
J. Immunol., March 15, 2004; 172(6): 3469 - 3479.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. M. Prins, F. Incardona, R. Lau, P. Lee, S. Claus, W. Zhang, K. L. Black, and C. J. Wheeler
Characterization of Defective CD4-CD8- T Cells in Murine Tumors Generated Independent of Antigen Specificity
J. Immunol., February 1, 2004; 172(3): 1602 - 1611.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D.-E. Hu, S. O. M. Dyke, A. M. Moore, L. L. Thomsen, and K. M. Brindle
Tumor Cell-Derived Nitric Oxide Is Involved in the Immune-Rejection of an Immunogenic Murine Lymphoma
Cancer Res., January 1, 2004; 64(1): 152 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. A. O'Mara and P. M. Allen
Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells
J. Immunol., January 1, 2004; 172(1): 310 - 317.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. A. Wilcox, K. Tamada, D. B. Flies, G. Zhu, A. I. Chapoval, B. R. Blazar, W. M. Kast, and L. Chen
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo
Blood, January 1, 2004; 103(1): 177 - 184.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
K M Brindle
Molecular imaging using magnetic resonance: new tools for the development of tumour therapy
Br. J. Radiol., December 1, 2003; 76(suppl_2): S111 - S117.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. S. Yang, C. E. Monken, and E. C. Lattime
Intratumoral Vaccination with Vaccinia-Expressed Tumor Antigen and Granulocyte Macrophage Colony-Stimulating Factor Overcomes Immunological Ignorance to Tumor Antigen
Cancer Res., October 15, 2003; 63(20): 6956 - 6961.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
K. A. Mitchell and B. P. Lawrence
Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Renders Influenza Virus-Specific CD8+ T Cells Hyporesponsive to Antigen
Toxicol. Sci., July 1, 2003; 74(1): 74 - 84.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. W. Hodge, D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom
Vaccine Therapy of Established Tumors in the Absence of Autoimmunity
Clin. Cancer Res., May 1, 2003; 9(5): 1837 - 1849.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-T. Huang, D. L. Huso, Z. Lu, T. Wang, G. Zhou, E. P. Kennedy, C. G. Drake, D. J. Morgan, L. A. Sherman, A. D. Higgins, et al.
CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction
J. Immunol., April 15, 2003; 170(8): 3945 - 3953.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Goldberg, P. Shrikant, and M. F. Mescher
In Vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)
J. Immunol., January 1, 2003; 170(1): 228 - 235.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. A. E. Harmala, E. G. Ingulli, J. M. Curtsinger, M. M. Lucido, C. S. Schmidt, B. J. Weigel, B. R. Blazar, M. F. Mescher, and C. A. Pennell
The Adjuvant Effects of Mycobacterium tuberculosis Heat Shock Protein 70 Result from the Rapid and Prolonged Activation of Antigen-Specific CD8+ T Cells In Vivo
J. Immunol., November 15, 2002; 169(10): 5622 - 5629.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L.-X. Wang, B.-G. Chen, and G. E. Plautz
Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion
J. Immunol., September 15, 2002; 169(6): 3314 - 3320.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Shrikant and M. F. Mescher
Opposing Effects of IL-2 in Tumor Immunotherapy: Promoting CD8 T Cell Growth and Inducing Apoptosis
J. Immunol., August 15, 2002; 169(4): 1753 - 1759.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. L. Tham and M. F. Mescher
The Poststimulation Program of CD4 Versus CD8 T Cells (Death Versus Activation-Induced Nonresponsiveness)
J. Immunol., August 15, 2002; 169(4): 1822 - 1828.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y.-G. Yang, J. Qi, M.-G. Wang, and M. Sykes
Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells
Blood, May 13, 2002; 99(11): 4207 - 4215.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. L. Tham, P. Shrikant, and M. F. Mescher
Activation-Induced Nonresponsiveness: A Th-Dependent Regulatory Checkpoint in the CTL Response
J. Immunol., February 1, 2002; 168(3): 1190 - 1197.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor
J. Immunol., December 1, 2001; 167(11): 6669 - 6677.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Bonnotte, N. Larmonier, N. Favre, A. Fromentin, M. Moutet, M. Martin, S. Gurbuxani, E. Solary, B. Chauffert, and F. Martin
Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System
J. Immunol., November 1, 2001; 167(9): 5077 - 5083.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. H. Ryan, J. A. Bristol, E. McDuffie, and S. I. Abrams
Regression of Extensive Pulmonary Metastases in Mice by Adoptive Transfer of Antigen-Specific CD8+ CTL Reactive Against Tumor Cells Expressing a Naturally Occurring Rejection Epitope
J. Immunol., October 15, 2001; 167(8): 4286 - 4292.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. L. Tham and M. F. Mescher
Signaling Alterations in Activation-Induced Nonresponsive CD8 T Cells
J. Immunol., August 15, 2001; 167(4): 2040 - 2048.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. W. Grosenbach, J. C. Barrientos, J. Schlom, and J. W. Hodge
Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects
Cancer Res., June 1, 2001; 61(11): 4497 - 4505.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. K. Helmich and R. W. Dutton
The Role of Adoptively Transferred CD8 T Cells and Host Cells in the Control of the Growth of the EG7 Thymoma: Factors That Determine the Relative Effectiveness and Homing Properties of Tc1 and Tc2 Effectors
J. Immunol., June 1, 2001; 166(11): 6500 - 6508.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Dalyot-Herman, O. F. Bathe, and T. R. Malek
Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC
J. Immunol., December 15, 2000; 165(12): 6731 - 6737.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Peng, J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen
T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-{gamma} Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics
J. Immunol., December 15, 2000; 165(12): 7116 - 7124.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. J. Roy, U. Gawlick, B. A. Orr, L. A. Rund, A. G. Webb, and D. M. Kranz
IL-12 Treatment of Endogenously Arising Murine Brain Tumors
J. Immunol., December 15, 2000; 165(12): 7293 - 7299.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. L. Warren, S. K. Bhatia, A. M. Acosta, C. E. Dahle, T. L. Ratliff, A. M. Krieg, and G. J. Weiner
APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells
J. Immunol., December 1, 2000; 165(11): 6244 - 6251.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen
Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression
J. Immunol., November 15, 2000; 165(10): 5738 - 5749.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.